摘要
Chiranjiv CHHABRA 医师
皮肤科医师
Integrating GLP-1 receptor agonists with noninvasive body countoring modalities for a holistic, more effective, and faster outcome
Objectives: GLP 1 receptor agonists are as a boon for individuals suffering from obesity or overweight .A large section of people with obesitty ,who want fat loss through non invasive body countouring modalities yaketaking very long to reacht their target weight and shape because of difficulty in persisting with changed diet plans . The GLP 1 drugs reduce appetite , food cravings and result in upto 25 % weight loss.Rapid loss results in skin laxity and muscle loss . Thus adding technologies for skin tightening , muscle stregthening and localized fat loss are beneficial in achieving a holistic outcome
Introduction: Glucagon-like peptide-1 (GLP-1) receptor agonists have revolutionized the treatment of obesity by promoting significant weight loss.Results of Non invasive fat loss modalities like Cryolipolysis,Green light laser,RF or Cavitation can be improved by adding these medications.Also rapid weight reduction induced by these medications often leads to aesthetic challenges like volume loss, skin laxity, and body contour irregularities. These consequences of GLP-1-induced weight loss can be minimised by modalities for tightening and muscle toning modalities like MNRF,RF and HIFEM.
Materials / method: As a scientific fat loss clinic we are integrating GLP-1 Rec agonist with other modalities.Identify patients with BMI above 29 .Their Hb1AC can be in range or raised. Few investigations are done and they are suggested a comprehensive plan with GLP -1&GIP rec Agonist along with the required modality.Their doses is monitored by a team of physicians and endocrinologist.During the treatment we identify key aesthetic concerns associated with GLP-1-induced weight loss and and depending on that add modalities like dermal fillers, biostimulatory agents and energy-based devices.
Results: A combination of GLP-1 Rec agonist along with other modalities delivers faster and more gratifying results instead of any standalone treatment.
Conclusion: As GLP-1 agonists become a key in treating obesity, their aesthetic implications have initiated a proactive response from aestheticians. To address facial volume loss, skin laxity, and body contour challenges we need combination of injectable treatments, energy-based devices, and, in some cases, surgical interventions. Future research should focus on understanding the molecular mechanisms of skin and fat changes and developing protocols &guidelines for treating this unique patient population
披露 - Chiranjiv CHHABRA
> 您是否获得了任何资金来支持您关于这个主题的研究?
不是
> 您在这项研究工作中是否获得过任何酬金、报酬或其他形式的补偿?
不是
> 您是否与任何可能与您研究中涉及的药物、材料或器械存在激烈竞争的实体有任何财务关系?
不是
> 您是否拥有或已申请过与您研究中所讨论的仪器、药物或材料相关的任何专利?
不是
这项工作没有任何直接或间接的资金支持。由作者自己承担责任。
Published on 2025年 7月 29日 - Recorded during IMCAS Asia 2025